Nerlynx Expanded Access Program (EAP)
NERLYNX may be provided to eligible patients, pursuant to Pierre Fabre Oncology Expanded Access Policy. PFO has partnered with Caligor Coghlan Pharma Services (CCPS) to manage the NERLYNX EAP. In some countries, some diseases are allowed to be taken into consideration while others are not. In these cases, a member of the CCPS team will be available to discuss with you. Website reserved to HCPs involved in the Nerlynx (neratinib) Expanded Access Program (EAP). For further information on Pierre Fabre Group, please go to https://www.pierre-fabre.com/en
SIGN INTO THE PORTAL BELOW:
Thank you for your interest in the Nerlynx® (neratinib) Extended Access Program. As of 15 November 2021, a new process is in place, whereby Pierre-Fabre Limited UK now manage this Compassionate Use Supply for UK patients. Please email: UK_QRVI@pierre-fabre.com with your request.